Polypharmacy Review in 10 Minutes: A Provider's Method for the Visit and the Exam

A polypharmacy review is a fixed sequence, not a conversation that wanders through the medication list: reconcile what the patient actually takes, attach every drug to a current indication, screen the list against the 2023 Beers Criteria and STOPP/START version 3, look for the cascades and omissions that lists miss, and then agree on one or two changes with a date to check them. In a focused visit the whole pass takes about 10 minutes. On the FNP and AGNP exams the same sequence answers the recurring item "which medication should be discontinued first," because the item writer built the vignette by walking the same steps in reverse.

Why the review matters

Older adults with multiple chronic conditions accumulate prescriptions from several clinicians, and each additional drug raises the probability of an interaction, an adverse event, a prescribing cascade, and nonadherence. The review also finds the opposite problem. START criteria exist because older patients are frequently undertreated for conditions where a drug has clear benefit (anticoagulation in atrial fibrillation, bone protection after a fragility fracture, an ACE inhibitor in HFrEF).

A workable definition for the visit: polypharmacy is present when the patient takes more drugs than are clinically indicated, whatever the count. The research cut-off of five or more is a trigger for review, not a diagnosis.

The 10-minute method

Step 1: reconcile

The chart list is wrong more often than it is right. Ask the patient to bring every container, including over-the-counter products, and read the labels with them. Ask specifically about sleep aids, allergy pills, pain relievers, antacids, laxatives, herbal products, and anything a spouse shares. Ask how each drug is actually taken, not how it was prescribed. Missing doses of an antihypertensive explains an "uncontrolled" blood pressure better than adding a fourth agent.

Step 2: match each drug to an indication

Write the indication beside each drug. Three findings follow. Drugs with no indication (a PPI started in hospital for stress-ulcer prophylaxis and never stopped). Drugs whose indication has resolved (an antidepressant from a bereavement 6 years ago, an allopurinol after a single gout flare). Duplications within a class (two anticholinergics, two sedatives, an SSRI plus a tricyclic). The Medication Appropriateness Index (Hanlon and colleagues, 1992) formalizes this with ten questions per drug: indication, effectiveness, dose, directions, practicality, drug-drug and drug-disease interactions, duplication, duration, and cost. You will not score it in a visit, but its first two questions (is there an indication, is the drug effective for it) carry most of the yield.

Step 3: screen with the tools

Two lists do the heavy lifting. The 2023 AGS Beers Criteria name the drugs to avoid in most older adults, the drug-disease pairs to avoid, interactions to avoid, and drugs to adjust by creatinine clearance. STOPP/START version 3 (2023) contains 133 STOPP criteria arranged by physiologic system and 57 START criteria that flag omissions. Add two numbers: the estimated creatinine clearance (Cockcroft-Gault, using actual body weight with judgment in obesity) and the anticholinergic burden, using the Anticholinergic Cognitive Burden scale (drugs scored 1 to 3; a cumulative score of 3 or more has been linked with cognitive decline in cohort studies).

The comparison below shows how the two lists overlap and where each adds something.

Step 4: hunt cascades and link symptoms to drugs

A prescribing cascade starts when an adverse effect is read as a new disease and treated with another drug. The classic one is a dihydropyridine calcium channel blocker causing ankle edema, treated with a loop diuretic, which then causes urinary urgency, treated with an anticholinergic, which causes confusion. Savage and colleagues (2020) documented the calcium channel blocker to diuretic cascade at population scale in older adults with hypertension. Other common cascades:

• NSAID raises blood pressure; a new antihypertensive is added.
• Cholinesterase inhibitor causes urinary incontinence; oxybutynin is added, which blunts the cholinesterase inhibitor and adds confusion.
• Antipsychotic or metoclopramide causes parkinsonism; levodopa or benztropine is added.
• Opioid causes constipation; laxatives accumulate; nausea is treated with promethazine.
• Thiazide causes hyperuricemia; allopurinol is started.
• Benzodiazepine causes daytime sedation; a stimulant or more caffeine is added, which worsens the insomnia.

The questions that expose a cascade are "when was this started" and "what was happening at the time." Then reverse the order: link the patient's current complaints to candidate drugs before accepting any as a new diagnosis. Falls point to sedatives, antihypertensives, anticholinergics, and hypoglycemics. Confusion points to anticholinergics, benzodiazepines, opioids, and H2 blockers. Edema points to calcium channel blockers, thiazolidinediones, and NSAIDs. Constipation points to anticholinergics, opioids, iron, and calcium. Orthostatic dizziness points to alpha blockers, diuretics, nitrates, and tricyclics.

Step 5: decide, prioritize, and document

Rarely can every flagged drug be changed in one visit. Prioritize in this order:

1. The drug causing a current symptom or an active harm (a benzodiazepine in a patient who fell, an NSAID with a rising creatinine, a sulfonylurea after hypoglycemia).
2. The drug with no indication or a resolved indication.
3. The highest-risk Beers or STOPP drug without a current symptom (an anticholinergic in a patient with cognitive impairment).
4. Preventive drugs whose time to benefit exceeds the patient's likely remaining life expectancy (a statin started for primary prevention at 88, a bisphosphonate beyond 5 years without high fracture risk, tight glycemic control with an A1c goal below 7.5 to 8 percent in frail adults).
5. START omissions, which add rather than remove, after the removals have settled.

Change one or two drugs at a time so that a benefit or a withdrawal effect can be attributed. Decide whether the drug needs a taper: benzodiazepines, Z-drugs, antidepressants, beta blockers, clonidine, gabapentinoids, opioids, and PPIs taken long term all do; a statin, an aspirin for primary prevention, a vitamin, or a short-course PPI can stop at once. Write the indication for every drug that stays, including the Beers drugs you choose to continue, with the reason.

Monitoring and follow-up intervals

Referral triggers

Refer to or consult a clinical pharmacist for a comprehensive medication review when the patient takes ten or more drugs, when kidney or liver function complicates dosing, when multiple prescribers are involved, or when a complex taper (multiple psychotropics, high-dose opioids) is needed. Refer to geriatrics when polypharmacy coexists with frailty, cognitive impairment, and recurrent falls, where goals of care should drive the plan. Refer to psychiatry or addiction medicine when a benzodiazepine or opioid taper is complicated by a use disorder or by severe anxiety relapse. Refer to the prescribing specialist before stopping a drug started for a condition you do not manage (antiplatelet after a recent stent, an antiepileptic, an immunosuppressant).

Patient and caregiver education

Deprescribing fails when the patient hears "the clinician is giving up on me." Frame each change as a response to a specific risk for this person: "this sleep aid is linked to falls and memory problems, and you have had both this year." Give a written list of what stays, what stops, what tapers and on what schedule, what symptoms to report, and the follow-up date. Ask the caregiver to manage a pill organizer for a week and bring it back. Tell the patient that symptoms during a taper are expected and temporary, and that pausing at the current dose is acceptable while stopping and restarting the full dose is not the plan.

How the exam tests this

• "Which medication should be discontinued first." The vignette lists five to eight drugs and one current problem (a fall, confusion, hypoglycemia, edema). The answer is the drug most plausibly causing the current problem, not the drug that merely appears on the Beers list. Read the problem before the list.
• The cascade item. A drug was started for a symptom that began after another drug was added. The correct option addresses the original drug (reduce amlodipine), not the symptom (add furosemide, add compression stockings).
• The omission item. An older adult with atrial fibrillation and a CHA2DS2-VASc score that warrants anticoagulation, or a fragility fracture without bone-protective therapy; the answer adds a drug. Candidates primed to subtract miss these.
• The renal number. The stem gives weight, age, sex, and creatinine; you are expected to estimate clearance and recognize that metformin, gabapentin, nitrofurantoin, or a DOAC needs adjustment or avoidance.
• The time-to-benefit item. An 89-year-old with advanced dementia on a statin for primary prevention or on tight glucose control; the answer relaxes the target or stops the drug.
• The taper trap. An option stops a benzodiazepine, beta blocker, or SSRI abruptly; another tapers it. The taper is right even when the drug should go.
• The adherence trap. Uncontrolled hypertension on three drugs; one option adds a fourth, another verifies adherence and home readings. Verify first.

Practice question

An 82-year-old man with hypertension, type 2 diabetes, benign prostatic hyperplasia, and chronic low back pain presents for an annual visit. He reports two falls in the past 3 months, both at night on the way to the bathroom, and his wife says he has seemed "foggy" for about 2 months. Medications: lisinopril 20 mg daily, amlodipine 10 mg daily, furosemide 20 mg daily (added 4 months ago for ankle swelling), glipizide 10 mg twice daily, tamsulosin 0.4 mg nightly, cyclobenzaprine 10 mg three times daily as needed (uses it nightly), and acetaminophen 1 g twice daily. Blood pressure is 118/68 mm Hg seated and 98/60 mm Hg standing with lightheadedness. Fingerstick glucose log shows several readings between 58 and 70 mg/dL before breakfast. A1c is 6.4 percent. Estimated creatinine clearance is 42 mL/min. Which of the following is the most appropriate first change?

• A. Stop furosemide, reduce amlodipine to 5 mg daily, and recheck orthostatic blood pressure in 2 weeks.
• B. Stop cyclobenzaprine, reduce glipizide to 5 mg daily, and reassess falls and glucose log in 2 weeks.
• C. Discontinue tamsulosin and begin oxybutynin 5 mg nightly to reduce nocturia.
• D. Add donepezil 5 mg nightly and order brain MRI for the cognitive change.

Answer: B. The two active harms are falls with cognitive fog and documented hypoglycemia, and the drugs most plausibly responsible are cyclobenzaprine (a strongly anticholinergic, sedating Beers muscle relaxant taken nightly) and glipizide (a sulfonylurea causing hypoglycemia with an A1c already below the frail-adult target). Those are changed first, with follow-up at 2 weeks. Option A addresses a real cascade (amlodipine edema treated with furosemide) and the orthostatic drop, and it is a correct second step, but it does not address the drug most directly tied to the nighttime falls and confusion or the hypoglycemia, which is the more urgent harm. Option C removes the appropriate BPH drug and adds an anticholinergic that would worsen cognition and retention. Option D treats a probable drug-induced cognitive change as neurodegenerative before the reversible causes have been removed.

Key points

Related NPPace guides

• Beers Criteria on the NP Exam: The Drugs to Avoid in Older Adults and What to Use Instead
• Dementia Screening in Primary Care: Mini-Cog, MoCA, the Reversible Causes Work-Up and Referral
• Deprescribing Benzodiazepines and Proton Pump Inhibitors: Tapers That Work and How to Monitor
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?